The emergence of new lung cancer molecular subtypes of RET fusion type and ROS1 fusion type has brought new vitality to the establishment of a new molecular typing diagnosis and treatment model (Takeuchi et al., 2012; Kohno et al., 2015). This evidence concerns the gene RET and lung cancer.